Moderna and Thermo Fisher Scientific honored for COVID-19 vaccine efforts

The Citeline Award acknowledges the COVE study, Moderna’s Period III vaccine trial that enrolled more than 30,000 individuals throughout the U.S.
(Photograph: USAF / Joshua J. Seybert)

WILMINGTON, NC (WWAY) – The PPD clinical exploration enterprise Thermo Fisher Scientific and Moderna, whose mRNA vaccine for COVID-19 has been administered to hundreds of thousands and thousands globally, were named “Clinical Exploration Crew of the Year” throughout the 2021 Citeline Awards.

This is the 2nd award that Thermo Fisher Scientific has obtained for their steps for the duration of the pandemic.

The Moderna and PPD teams labored carefully with the Biomedical State-of-the-art Investigate and Enhancement Authority and the National Institutes of Health, including National Institute of Allergy and Infectious Diseases’ COVID-19 Avoidance Community, to perform the Phase III COVE analyze underneath Operation Warp Pace.

Moderna’s COVID-19 vaccine was offered beneath emergency use authorization in the U.S. starting in December 2020, and in January 2022, the U.S. Meals and Drug Administration permitted the biologics license application for the vaccine, marketed as Spikevax®, to avert COVID-19 in individuals 18 years of age and older.

“This recognition honors our robust collaboration with Moderna and reinforces our shared dedication to create daily life-conserving vaccines and therapies,” said David M. Johnston, Ph.D., senior vice president and president, scientific exploration, Thermo Fisher Scientific. “We’re thrilled to keep on supporting Moderna on subsequent-era, multivalent and variant-certain vaccines in Period I-III experiments by our infrastructure, experience and complementary expert services.”

The Citeline Awards figure out accomplishments throughout the biopharmaceutical industry and honor the highest achievers. Citeline offered the award all through its once-a-year ceremony, held in Boston.

The PPD scientific investigation workforce has supported Moderna’s analysis initiatives due to the fact 2016 throughout its expanding portfolio, including vaccines, oncology, exceptional conditions and autoimmune ailments.

In February 2022, Thermo Fisher declared a 15-12 months strategic collaboration settlement with Moderna for dedicated big-scale producing in the U.S. of Spikevax® and other investigational mRNA medicines in its pipeline.